中文

IDEXX jumps 22% on a beat and raise despite fewer vet visits

By · AI-assisted, human-reviewed and edited · · Updated · 8 sources · Fact-checked · 4 min read

Why is IDEXX Laboratories stock up today?

IDEXX, which sells tests and lab services to vets, beat third-quarter forecasts and raised its 2026 sales and profit outlook, even though U.S. clinical visits fell an estimated 1.8%, by its count. The shares closed up 22% at $671.64 on Monday. They had closed on Friday 28% below their record close in November 2025.

What it means

What changed
IDEXX raised its 2026 forecasts to revenue of $4.74–4.77 billion and EPS of $14.96–15.16, after third-quarter sales and profit beat estimates.
What hasn't changed
U.S. vet visits are still falling, an estimated 1.8% in the quarter; IDEXX's CEO says its growth doesn't rely on visits rising.
Next · Jan 18, 2027 (scheduled)
IDEXX's investor session at the VMX conference, focused on its next in-clinic analyzer, MultiCue Dx.
Move
▲ 21.8%
Price
$551.21 → $671.64
Value gained
~$9.5B
Q3 adjusted EPS
$3.96 vs $3.72 est.
Revenue guide midpoint
+$32M to ~$4.75B
US vet visits, Q3
−1.8% (IDEXX estimate)

Prices: Nasdaq historical close, Nov 2, 2026 · Company data: 10-Q, Jun 30, 2026 · What these numbers mean

Closing prices: $551.21 on Oct 30 and $671.64 on Nov 2, 2026, per Nasdaq and Yahoo Finance; StockAnalysis shows $670.10. Day's range $620.20–673.19 per Nasdaq.

Snapshot at the Nov 2, 2026 close

Enterprise value
$53.7B
Price/sales
11.6×
EV/sales
11.8×
P/E
46.4×
Price/FCF
42.2×
Revenue growth
+13%
Net debt
$772M

Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Aug 4, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $671.64 (Nasdaq historical close); 78.8 million shares (common shares on the cover page of the 10-Q filed Aug 4, 2026). n/m = not meaningful (e.g. negative earnings).

What happened

IDEXX’s shares closed up 22% on Monday, the day it reported third-quarter results above analysts’ forecasts and raised its full-year outlook.

  • IDEXX sells diagnostics for pets: analyzers that vets keep in their clinics, the tests run on them, outside lab services and practice software. It reported before the market opened on Monday, Nov 2, and held its call at 8:30 a.m. ET.
  • Third-quarter revenue rose 10% to $1.21 billion, against an estimate of $1.19 billion, Investing.com reported. Comparable earnings per share (EPS), IDEXX’s adjusted measure, was $3.96 against an estimate of $3.72; EPS as reported was $4.01, up 18%.
  • Revenue from the tests and lab services vets buy repeatedly, which IDEXX calls CAG (Companion Animal Group) Diagnostics recurring revenue, grew 11%. Sales of consumables for its in-clinic analyzers rose 14%.
  • IDEXX placed more than 1,900 of its inVue Dx analyzers, which examine cell samples in the clinic, bringing the installed base to nearly 11,000.
  • It raised its 2026 revenue forecast to $4.741–4.767 billion from $4.700–4.745 billion, and its EPS forecast to $14.96–15.16 from $14.69–14.94. Both new ranges are above analysts’ estimates, Investing.com reported.
  • It lowered its 2026 operating margin forecast (operating profit as a share of revenue) to 32.1–32.3% from 32.3–32.5%. The new range includes about 0.3 percentage point of costs from its purchase of CoVet, a maker of artificial intelligence (AI) assistant software for vets, CFO Andrew Emerson said on the call.
  • The shares closed Friday at $551.21. On Monday they closed at $671.64, up 21.8%, per Nasdaq data. Based on the 78.8 million shares outstanding on July 31, per its second-quarter filing, that is about $9.5 billion of added market value, by our calculation.

The numbers that mattered

Measure Q3 2026 Estimate or prior
Revenue $1.21B, +10% ~$1.19B estimate
Comparable EPS $3.96 $3.72 estimate
Recurring pet-diagnostics revenue +11% 2026 guide raised to +11.0–11.7% (was +10.1–11.3%)
2026 revenue guide $4.741–4.767B Was $4.700–4.745B; ~$4.72B estimate
2026 EPS guide $14.96–15.16 Was $14.69–14.94; $14.88 estimate
2026 operating margin guide 32.1–32.3% Was 32.3–32.5%

Sources: IDEXX’s Q3 2026 results release; estimates per Investing.com.

Why the market reacted this way

The beat came after the stock had fallen 28% from its record, over a period in which IDEXX reported fewer visits to U.S. vet clinics.

  • The shares had closed on Friday 28% below their record close of $766.68 on Nov 25, 2025, and hit a low close of $504.70 on Sept 11, 2026, according to Yahoo Finance data.
  • In February, the shares fell about 6% in morning trade after IDEXX’s 2026 forecast assumed a roughly 2% decline in U.S. same-store clinical visits (visits with a vet at the same practices, compared with a year earlier) and slightly lower price increases than in 2025, Reuters reported.
  • Visits are still falling: Emerson estimated that U.S. same-store clinical visits fell 1.8% in the third quarter. Yet U.S. recurring diagnostics revenue grew 10%. IDEXX attributed its recurring diagnostics growth to higher testing volumes at existing clinics, new products, customer gains and a larger base of its premium analyzers.
  • CEO Mike Erickson said on the call that “our growth doesn’t rely on seeing positive visits,” and that IDEXX was “well on track to exceed” its goal of 5,500 inVue Dx placements in 2026.
  • The gain grew during the morning. Investing.com reported the shares up 6.1% in premarket trading in a report published at 8:24 a.m., before the call, and up 17.2% at $646 in one published at 9:39 a.m. We found no report tying the extra gain to a specific comment on the call.
  • Asked whether CoVet would change its margin plans for 2027, Emerson said IDEXX had not moved away from its long-term target of widening its operating margin by 0.5 to 1 percentage point a year.

Does this change IDEXX’s future?

What did NOT change

  • U.S. clinical visits are still declining, and Emerson said the economy “continues to remain a little bit more of a challenge.”
  • Price increases are still part of the growth: Emerson said third-quarter recurring diagnostics growth included about 4% from higher net prices worldwide.

What DID change

  • IDEXX now expects higher 2026 revenue and EPS than it did in August, mainly because recurring diagnostics revenue has grown faster than it forecast.
  • It expects a slightly lower operating margin this year, which it attributes to the CoVet purchase.

Our read

The quarter showed IDEXX growing recurring revenue by double digits while U.S. clinical visits fell. Its fourth-quarter results and first 2027 outlook, including what it assumes for visits, will show whether that continues.

What to watch next

Jan 18, 2027 (scheduled)
IDEXX's investor and analyst session at the VMX veterinary conference, highlighting its next in-clinic analyzer, MultiCue Dx.
Early February 2027 (expected)
Fourth-quarter results and the first 2027 outlook, including its assumption for U.S. clinical visits; IDEXX has not announced the date.
Ongoing
inVue Dx placements against the company's goal of more than 5,500 in 2026, and the cost of integrating CoVet.

Quick questions

What does IDEXX sell?

Mainly diagnostics for pets: analyzers that vets use in their clinics, the tests run on them, outside lab testing and practice software. It also sells tests for water quality and farm animals.

What is comparable EPS?

IDEXX's adjusted earnings per share, which strips out currency moves, tax benefits from share-based pay and one-off items. Third-quarter EPS was $4.01 as reported and $3.96 on that comparable basis.

Why do vet clinic visits matter?

Most of IDEXX's revenue comes from tests that vets run on patients, so fewer visits can mean fewer tests. IDEXX estimates U.S. same-store clinical visits fell 1.8% in the third quarter, while its U.S. recurring diagnostics revenue grew 10%.

Updates

  • : Updated to the Nov 2 close: up 21.8% at $671.64 (earlier version: up 19.8% at $660.32 at 9:55 a.m. ET).

About IDEXX Laboratories: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.